Menu
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. The company invents unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases-while making commonly treatable cases even easier-to meet the full spectrum of patient needs. Accuray is dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as they partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide.
1310 Chesapeake Ter
Sunnyvale, California 94089
Phone: 14087164600
www.accuray.com
Accuray Incorporated (NASDAQ:ARAY) closed Thursday at $2.03 per share, up from $1.93 a day earlier. While Accuray Incorporated has overperformed by 5.18%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARAY fell by -63.22%, with highs and lows ranging from $5.93 to $1.70, whereas the simple […]
Accuray looks undervalued on discounted cash flow. Read why ARAY stock could well move before company reaches and holds $100M/quarter in orders.
Accuray Incorporated (NASDAQ:NASDAQ:ARAY) Q1 2023 Results Conference Call November 02, 2022 04:30 AM ET Company Participants Ken Mobeck - Vice President of Finance and Investor Relations…
WASHINGTON (dpa-AFX) - Accuray Incorporated (ARAY) released Loss for its first quarter that increased from the same period last year and missed the Street estimates.The company''s bottom line total…
Accuray press release (NASDAQ:ARAY): Q1 GAAP EPS of -$0.06 misses by $0.02.Revenue of $96.49M (-10.2% Y/Y) misses by $3.45M.Gross orders of $69.8 million, were flat versus the prior fiscal…
Strong customer demand. Navigating FX and Supply Chain Challenges. Company reiterates full year guidance. SUNNYVALE, Calif., Nov. 2, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2023 ended September 30, 2022….
Accuray (ARAY) said the registration dossier for Tomo C radiation therapy system for the Type B market was submitted to China''s National Medical Products Administration…
SUNNYVALE, Calif., Nov. 1, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy system for the Type B market has been submitted to the Chinese National Medical Products…
Collaboration places emphasis on personalized medicine; brings together key precision diagnostic and treatment delivery tools aimed at creating shorter, more comfortable and more effective treatments for patients CHICAGO and SUNNYVALE, Calif. , Oct. 21, 2022 /PRNewswire/ -- GE Healthcare and
Accuray (ARAY) said it had launched its CyberKnife platform in Africa for more patients to receive treatments with stereotactic radiosurgery ((SRS)) and stereotactic body radiation…
World''s Only Robotic Radiation Therapy Device Delivers Extremely Precise Treatments in Just 1 to 5 Out- Patient Sessions SUNNYVALE, Calif. , Sept. 30, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company is expanding its global footprint with the introduction of its